In combination with carboplatin and paclitaxel, Nexavar is contra-indicated in patients with squamous cell lung cancer.
- TRADE NAME: Nexavar (Bayer)
- INDICATIONS: Advanced renal cell carcinoma
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), FLT3 (FMS-like tyrosine kinase 3) inhibitor, RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 25–48 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bevacizumab, Carbamazepine, Clozapine, Conivaptan, Coumarins, CYP3A4 inducers, Darunavir, Delavirdine, Dexamethasone, Digoxin, Docetaxel, Doxorubicin, Efavirenz, Indinavir, Irinotecan, Neomycin, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort, Telithromycin, Voriconazole, Warfarin
- See adverse reactions attributed to class:
Angiogenesis inhibitor / antiangiogenic agent
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
FLT3 (FMS-like tyrosine kinase 3) inhibitor
RET (Rearranged during Transfection) kinase inhibitor
Vascular endothelial growth factor (VEGF) inhibitor / antagonist
Please login to view the rest of this drug profile.
Page last updated 05/28/2026
